secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2025-10-08T23:59:59+00:00
Accession:  0001193125-25-234001
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio CFO resigns; CEO takes interim CFO role
-------------------------------------------------

- CFO Vineet Agarwal resigns effective Oct 17, 2025; will advise for 30 days.
- CEO Dr. Ram Aiyar named interim CFO in addition to CEO duties, no extra compensation.
- Separation benefits include 9 months base salary ($352,500), prorated FY2025 target bonus ($149,400), and extended option exercise through Mar 31, 2027.
- Departure is not related to any disagreement with management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312525234001/0001193125-25-234001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312525234001/krro-20251007.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-234001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer